Search results for: Hans-Helmut Konig
Filter search results
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
…by the two main factors playing a role: (i) the cost of R&D for orphan drugs as compared to non-orphans and, (ii) patient population sizes targeted by orphans and non-orphans.…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…(i) the cost of R&D for orphan drugs as compared to non-orphans and, (ii) patient population sizes targeted by orphans and non-orphans. Research shows that, on average, the estimated research…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…for orphan drugs are likely to be smaller than for non-orphans. The study estimates differences in the research and development costs between orphan and non-orphans using the number of patients…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…of Health Economics. 22(2), 151-185. [6] 13% for phases 1-3. Paul et al. (2010) [7] Hansen (1979) [8] Paul et al. (2010) [9] Hansen (1979) [10] DiMasi et al (2003)…
Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing
4 October 2011
…of a Centralized European Pricing and Reimbursement Agency,’ moderated by Mark Schulpher, University of York, and including also Hans-Georg Eichler, EMA. Should an agency similar in structure to EMA be…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…England from authorisation via the centralised procedure to access in the NHS is presented in Figure 2. Figure 2: Orphans vs non-orphans, from authorisation to availability in the NHS in…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…speed-up access to treatments including orphans. Of critical importance to meeting this objective, however, is ensuring evidentiary standards applied to rare disease treatments are realistic and proportionate, and that the…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
27 September 2018, 11:00pm
…of the 2014 New Statesman SPERI Prize in Political Economy, the 2015 Hans-Matthöfer-Preis, and the 2018 Leontief Prize for Advancing the Frontiers of Economic Thought. She was named as one…